Search

Displaying results 6841 - 6850 of 10000 in total
  1. Drug

    MBP-091

    go.drugbank.com/drugs/DB17741
    Experimental

    MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]

  2. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits

  3. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

  4. Drug

    VaxSyn

    go.drugbank.com/drugs/DB17827
    Investigational

    VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).

  5. Drug

    DS-1211

    go.drugbank.com/drugs/DB17837
    Investigational

    DS-1211 is a potent and selective novel small molecule tissue-nonspecific alkaline phosphatase (TNAP) inhibitor.[A259786]

    Synonyms: Ac-D-Leu-OH
  6. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    OAV201 is a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter

  7. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    SAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  8. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    QRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.

  9. Drug

    MANF

    go.drugbank.com/drugs/DB17885
    Experimental

    MANF is a human recombinant mesencephalic, astrocyte-derived neurotrophic factor.

  10. Drug

    GIVI-MPC

    go.drugbank.com/drugs/DB17905
    Experimental

    GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.